![Adrian Newman-Tancredi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Adrian Newman-Tancredi
Amministratore Delegato presso Neurolixis, Inc.
Posizioni attive di Adrian Newman-Tancredi
Società | Posizione | Inizio | Fine |
---|---|---|---|
Neurolixis, Inc.
![]() Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Amministratore Delegato | - | - |
Fondatore | - | - | |
Presidente | - | - |
Storia della carriera di Adrian Newman-Tancredi
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Chief Executive Officer | 1 |
Founder | 1 |
President | 1 |
Settori
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Neurolixis, Inc.
![]() Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |